1. Safe and neuroprotective vectors for long-term traumatic brain injury gene therapy.
- Author
-
Blanco-Ocampo D, Cawen FA, Álamo-Pindado LA, Negro-Demontel ML, and Peluffo H
- Subjects
- Animals, Brain metabolism, Brain Injuries, Traumatic genetics, Disease Models, Animal, Infusions, Intraventricular, Lentivirus genetics, Male, Microglia metabolism, Neuroimmunomodulation genetics, Neuroimmunomodulation immunology, Neuroprotective Agents therapeutic use, Parenchymal Tissue, Rats, Rats, Wistar, Recombinant Proteins metabolism, Recombinant Proteins pharmacology, Brain Injuries, Traumatic therapy, Genetic Therapy methods, Neuroprotection genetics
- Abstract
Traumatic brain injury (TBI) is a complex and progressive brain injury with no approved treatments that needs both short- and long-term therapeutic strategies to cope with the variety of physiopathological mechanisms involved. In particular, neuroinflammation is a key process modulating TBI outcome, and the potentiation of these mechanisms by pro-inflammatory gene therapy vectors could contribute to the injury progression. Here, we evaluate in the controlled cortical impact model of TBI, the safety of integrative-deficient lentiviral vectors (IDLVs) or the non-viral HNRK recombinant modular protein/DNA nanovector. These two promising vectors display different tropisms, transduction efficiencies, short- or long-term transduction or inflammatory activation profile. We show that the brain intraparenchymal injection of these vectors overexpressing green fluorescent protein after a CCI is not neurotoxic, and interestingly, can decrease the short-term sensory neurological deficits, and diminish the brain tissue loss at 90 days post lesion (dpl). Moreover, only IDLVs were able to mitigate the memory deficits elicited by a CCI. These vectors did not alter the microglial or astroglial reactivity at 90 dpl, suggesting that they do not potentiate the on-going neuroinflammation. Taken together, these data suggest that both types of vectors could be interesting tools for the design of gene therapy strategies targeting immediate or long-term neuropathological mechanisms of TBI.
- Published
- 2020
- Full Text
- View/download PDF